Compare JJSF & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | VIR |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1995 | 2019 |
| Metric | JJSF | VIR |
|---|---|---|
| Price | $89.47 | $9.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $140.00 | $19.43 |
| AVG Volume (30 Days) | 239.7K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,022,038,000.00 | $68,556,000.00 |
| Revenue This Year | $0.30 | $270.22 |
| Revenue Next Year | $1.70 | N/A |
| P/E Ratio | $45.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $4.25 |
| 52 Week High | $116.32 | $11.66 |
| Indicator | JJSF | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 65.76 | 51.93 |
| Support Level | $80.49 | $8.43 |
| Resistance Level | $96.42 | $9.80 |
| Average True Range (ATR) | 2.80 | 0.40 |
| MACD | 0.90 | 0.04 |
| Stochastic Oscillator | 82.79 | 58.10 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.